This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Palomba, S. Articles by Zullo, F. Search for Related Content PubMed PubMed Citation Articles by Palomba, S. Articles by Zullo, F.

Raloxifene Administration in Women Treated with Gonadotropin-Releasing Hormone Agonist for Uterine Leiomyomas: Effects on Bone Metabolism

Chair of Obstetrics and Gynecology (S.P., M.M., T.R., F.Z.), University of Catanzaro, 88100 Catanzaro, Italy; Departments of Molecular and Clinical Endocrinology and Oncology (F.O., G.L., A.C.) and Gynecology, Obstetrics and Human Reproduction (M.P., C.N.), University of Naples "Federico II", 80131 Naples, Italy; and Department of Obstetrics and Gynecology (P.M.), University of Messina, 98166 Messina, Italy

Address all correspondence and requests for reprints to: Dr. Stefano Palomba, Via Nicolardi 188, Napoli 80131, Italy. E-mail: stefanopalomba{at}tin.it.

Abstract

This prospective randomized, single-blind, placebo-controlled clinical trial was performed to evaluate the efficacy of raloxifene in preventing the bone loss associated with GnRH agonist (GnRH-a) administration.

One hundred premenopausal women with uterine leiomyomas were treated with leuprolide acetate depot at a dosage of 3.75 mg/d for 28 d and then randomized into two groups to receive raloxifene hydrochloride at 60 mg/d (group A) or placebo (1 tablet/d; group B). Bone mineral density (BMD) and serum bone metabolism markers were evaluated at admission and after six treatment cycles.

Posttreatment BMD differed significantly from baseline BMD in group B but not in group A. BMD was significantly higher in group A than in group B. In group A, serum osteocalcin and bone alkaline phosphatase levels and urinary deoxypyridinoline and pyrilinks-D excretion were unchanged vs. baseline. Differently, posttreatment concentrations of these bone turnover markers were significantly lower in group B compared with baseline and group A values.

In conclusion, raloxifene prevents GnRH-a related bone loss in premenopausal women with uterine leiomyomas.

This article has been cited by other articles:

				S. Palomba, F. Orio Jr, T. Russo, A. Falbo, T. Cascella, P. Doldo, C. Nappi, G. Lombardi, P. Mastrantonio, and F. Zullo Long-term effectiveness and safety of GnRH agonist plus raloxifene administration in women with uterine leiomyomas Hum. Reprod., June 1, 2004; 19(6): 1308 - 1314. [Abstract] [Full Text] [PDF]

				M. L. Gourlay and S. A. Brown Clinical Considerations in Premenopausal Osteoporosis Arch Intern Med, March 22, 2004; 164(6): 603 - 614. [Abstract] [Full Text] [PDF]

				S. Palomba, T. Russo, F. Orio Jr, A. Sammartino, F. M. Sbano, C. Nappi, A. Colao, P. Mastrantonio, G. Lombardi, and F. Zullo Lipid, glucose and homocysteine metabolism in women treated with a GnRH agonist with or without raloxifene Hum. Reprod., February 1, 2004; 19(2): 415 - 421. [Abstract] [Full Text] [PDF]

				S. Palomba, T. Russo, F. Orio Jr, L. Tauchmanova, E. Zupi, P. L. B. Panici, C. Nappi, A. Colao, G. Lombardi, and F. Zullo Effectiveness of combined GnRH analogue plus raloxifene administration in the treatment of uterine leiomyomas: a prospective, randomized, single-blind, placebo-controlled clinical trial Hum. Reprod., December 1, 2002; 17(12): 3213 - 3219. [Abstract] [Full Text] [PDF]